Trial Profile
A Phase I, Randomised, Double-blind, Placebo-controlled study to evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple ascending doses of GDC-0853 in Healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2018
Price :
$35
*
At a glance
- Drugs Fenebrutinib (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus; Urticaria
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 07 Mar 2018 New trial record
- 27 Feb 2018 Results published in the Clinical Pharmacology and Therapeutics